- Strong portfolio of IP for stem-cell expansion of Hematapoietic Stem Cells (HSC)
- Significant competitive advantage in global market
- Significant opportunities fromCytomatrix technologies:
- Stem cell blood products
- Bio Reactor technologies for range of stem cell applications
- Short nanofiber production for broad range of industries
Manifex currently has two exciting investments in the portfolio. Cytomatrix is a biotech firm with stem cell therapeutic blood product. Circa Group is a ‘green chemicals’ firm.
- Breakthrough technology for specialty chemical, Levoglucosenone (LGN).
- Diverse range of applications – pharmaceutical, agrichemicals, fragrances and green solvents (Cyrene)
- Increasing market awareness by European and US chemical/pharmaceutical manufacturers
- Scaling-up for commercial plant within 18-24 months